Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.
Daniel Weiss

Dr. Daniel Weiss MD

President, Weiss Consulting Groups, Inc.

What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Member of the Healthcare Council

Council Member Biography

Daniel Weiss, MD, FACC, is a Clinical Cardiac Electrophysiologist with Florida Arrhythmia Consultants and the Founder and President of his own consultancy, Weiss Consulting Groups, which provides consultation services to the business world on medical topics and to medical drug and device startup companies. He is currently the Chief Medical Officer for Vicor Medical Technologies, specializing in Medical Devices and Supplies. Through Dr. Weiss’ work as a consultant he has worked as Chief Medical Officer of a startup biotech company, Chief Medical Advisor of an engineering and software consulting firm, and chief cardiology advisor to a pharmaceutical corporation. He has been an investigator on numerous studies, including AVID, MADIT II, SCD-HeFT, as well as several other NIH studies. Dr. Weiss also serves as a consultant to several implantable cardiac device companies, including Medtronic, St Jude, and Guidant. (This is me - Update Profile)


Employment History

1996 - Unspecified
President, Weiss Consulting Groups, Inc.
1994 - Unspecified
Clinical Cardiac Electrophysiologist , ARRHYTHMIA CONSULTANTS FLORIDA PA

GLG NewsSM Analyses by Daniel Weiss(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

Medtronic - the new Guidant?

October 18, 2007

Medtronic Pulls Heart Device Wires | www.thestreet.com

The current recall is yet another in the world of cardiac rhythm devices. The ICD market is already shakey and may be adversely affected. Will Medtronic's reputation suffer?

TB-402 - the type of anticoagulant patients and physicians are looking for as a warfarin replacement

September 17, 2007

ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 | www.pipelinereview.com

TB-402 is a new anticoagulant candidate that seeks to fill a desperate unmet need in a variety of different medical conditions. It would be easily administered with a low risk of patient noncompliance, have reversible effects, and potentially safer than currently available alternatives.

Leading institutions connect with Daniel Weiss through GLG

GLG Live Meetings with Daniel Weiss(?)

Daniel Weiss has not participated in any GLG Live Meetings.

View all GLG Live Meetings in Healthcare